Immunologische Ex-vivo-Untersuchungen zum Wirkmechanismus von humanen &lt;i&gt;Enterococcus-faecalis&lt;/i&gt;-Bakterien (Symbioflor 1&lt;sup&gt;®&lt;/sup&gt;) an Miniaturschweinen

Ottendorfer, D.; Zimmermann, K.; Taborski, Brigitte; Thoma, William J.; Thoma, H. K.; Schade, I.

doi:10.1159/000210172

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data from animals showed that the amount of IgA antibodies in the saliva was significantly increased after the DSM 16440 strain supplementation. That in itself was caused by the stimulation of the plasma cells' proliferation in the mesenteric lymph nodes [25,27]. IgAs are antibodies mainly existing in MALT, specifically in the mucus layer.…”

Section: Probiotic Strains Of Enterococcus Faecalis and Their Impact ...mentioning

confidence: 99%

From the Friend to the Foe—Enterococcus faecalis Diverse Impact on the Human Immune System

Daca,

Jarzembowski

2024

IJMS

View full text Add to dashboard Cite

Enterococcus faecalis is a bacterium which accompanies us from the first days of our life. As a commensal it produces vitamins, metabolizes nutrients, and maintains intestinal pH. All of that happens in exchange for a niche to inhabit. It is not surprising then, that the bacterium was and is used as an element of many probiotics and its positive impact on the human immune system and the body in general is hard to ignore. This bacterium has also a dark side though. The plasticity and relative ease with which one acquires virulence traits, and the ability to hide from or even deceive and use the immune system to spread throughout the body make E. faecalis a more and more dangerous opponent. The statistics clearly show its increasing role, especially in the case of nosocomial infections. Here we present the summarization of current knowledge about E. faecalis, especially in the context of its relations with the human immune system.

show abstract

Section: Probiotic Strains Of Enterococcus Faecalis and Their Impact ...mentioning

confidence: 99%

From the Friend to the Foe—Enterococcus faecalis Diverse Impact on the Human Immune System

Daca,

Jarzembowski

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Studie mit dem hier untersuchten Testpräparat im Vergleich zu Plazebo[20], wurde ein Anstieg der IgA Antikörper im Speichel der Versuchstiere nach peroraler Gabe des Präparates nachgewiesen, was gut mit den diskutierten Wirkmechanismen peroral applizierter bakterieller Immunstimulantien übereinstimmt. Untersuchungen zur Zytokin-Freisetzung tierischer und humaner Leukozyten nach Inkubation mit dem hier untersuchten Testpräparat…”

unclassified

Einfluß eines bakteriellen Immunstimulans (humane Enterococcus faecalis-Bakterien) auf die Rezidivhäufigkeit bei Patienten mit chronischer Bronchitis

Habermann

Zimmermann

Skarabis

et al. 2011

Arzneimittelforschung

View full text Add to dashboard Cite

The following double-blind, placebo-controlled, multicenter study investigated the influence of a bacterial immunostimulant (Symbioflor 1, cells and autolysate of human Enterococcus faecalis) on the occurrence of relapses in patients with chronic recurrent bronchitis (n = 136; placebo n = 66, verum n = 70) in a 6 months treatment period and a follow-up period of 8 months, compared to placebo. Under verum 39 incidents of relapses were recorded, which was about 60% the number observed among the patients treated with placebo (66 incidents). The verum preparation exhibited superior clinical efficacy compared to placebo (p = 0.001) in the Kaplan-Meier test. This better clinical efficiency of the test preparation was particularly observed during the treatment period, with 12 vs. 27 relapses (p = 0.013), but less during the follow-up observation period, with 27 vs. 39 relapses (p = 0.127). In addition, the time span until occurrence of the first relapse was clearly longer under verum (699 days) than under placebo (334 days) and after the end of the observation period 91% of patients under verum experienced only one relapse compared to 62% in the placebo group (p = 0.01). Severity of relapses under verum was also reduced significantly (chi 2; p = 0.001. Only 4 patients under verum required antibiotic therapy compared to 13 patients under placebo. Verum was equally well tolerated as placebo, with no serious side effects in either group. No changes in laboratory tests--haematology and clinical chemistry--were observed. It can be concluded, that previously demonstrated immunomodifying effects of the test preparation have clinical relevance for the treatment of chronic recurrent bronchitis because not only the number but also the severity of acute relapses could be clearly reduced. This is discussed in view of the current literature.

show abstract

Immunologische Ex-vivo-Untersuchungen zum Wirkmechanismus von humanen <i>Enterococcus-faecalis</i>-Bakterien (Symbioflor 1<sup>®</sup>) an Miniaturschweinen

Cited by 2 publications

References 2 publications

From the Friend to the Foe—Enterococcus faecalis Diverse Impact on the Human Immune System

From the Friend to the Foe—Enterococcus faecalis Diverse Impact on the Human Immune System

Einfluß eines bakteriellen Immunstimulans (humane Enterococcus faecalis-Bakterien) auf die Rezidivhäufigkeit bei Patienten mit chronischer Bronchitis

Contact Info

Product

Resources

About